IDWEEK 2016 – Adult Infectious Diseases

High Efficacy With Sofosbuvir/Velpatasvir + Voxilaprevir for Pangenotypic HCV

For patients with hepatitis C virus (HCV) infection genotype (GT) 1-6, treatment with sofosbuvir/velpatasvir plus voxilaprevir (GS-9857) once daily was safe, well tolerated, and highly effective in treatment-naive and treatment-experienced patients, reported Ronald Nahass, MD, FIDSA, FSHEA, from ID Care, Inc., Hillsborough, NJ, at IDWeek 2016.